News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

miRagen Therapeutics Release: Therapeutic Dosing of Synthetic AntimiR Further Demonstrates the Potential of microRNA-208 Inhibition in Treatment of Chronic Heart Failure


9/7/2011 9:54:18 AM

BOULDER, Colo.--(BUSINESS WIRE)--miRagen Therapeutics, Inc., a preclinical-stage biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced that new preclinical data published in today’s online edition of Circulation suggest that therapeutic inhibition of microRNA-208 (miR-208) may improve cardiac function and survival rates during heart failure.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES